Suppr超能文献

静脉注射免疫球蛋白加泼尼松龙治疗的川崎病患儿肾上腺抑制的高发生率。

High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone.

作者信息

Goto Masahiro, Miyagawa Naoyuki, Kikunaga Kaori, Miura Masaru, Hasegawa Yukihiro

机构信息

Division of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center, Fuchu 183-8561, Japan.

出版信息

Endocr J. 2015;62(2):145-51. doi: 10.1507/endocrj.EJ14-0385. Epub 2014 Oct 22.

Abstract

Combination treatment with intravenous immunoglobulin (IVIG) plus prednisolone, newly designed for children with severe Kawasaki disease (KD), reduces coronary artery abnormalities significantly. As prednisolone is administered for approximately 20 days in this regimen, we examined whether adrenal function of the treated patients is suppressed. A prospective study was performed at one medical institution in 21 children with KD (age range 0.3-10.4 years, median 3.1 years) who were treated with the regimen between February and June, 2012. We assessed cortisol and ACTH values before the initiation and after the cessation of prednisolone administration as well as peak cortisol and ACTH values at corticotropin-releasing hormone (CRH) stimulation tests, which were repeated 0, 2, and 6 months after the treatment. Morning cortisol and ACTH values after the cessation of prednisolone treatment were suppressed. Peak cortisol values at the first CRH stimulation test ranged from 5.1 to 25.4 μg/dL and were less than 20 μg/dL in 17 of 21 patients, but were restored to more than 14.6 μg/dL in all patients by 6 months after the prednisolone treatment. A significant positive correlation was observed between cortisol values at 09:00 h after the prednisolone treatment and peak cortisol values at the following CRH stimulation test (r = 0.727, p < 0.001). We conclude that adrenal suppression can occur in a high proportion of children with KD treated with IVIG plus prednisolone, despite rather short duration and relatively small amounts of administered glucocorticoids.

摘要

新设计的用于治疗重症川崎病(KD)患儿的静脉注射免疫球蛋白(IVIG)联合泼尼松龙疗法,可显著降低冠状动脉异常的发生率。由于在此治疗方案中泼尼松龙的给药时间约为20天,我们研究了接受治疗的患儿的肾上腺功能是否受到抑制。2012年2月至6月期间,在一家医疗机构对21例接受该治疗方案的KD患儿(年龄范围0.3 - 10.4岁,中位数3.1岁)进行了一项前瞻性研究。我们评估了泼尼松龙给药开始前和停止后皮质醇和促肾上腺皮质激素(ACTH)的值,以及促肾上腺皮质激素释放激素(CRH)刺激试验中的皮质醇和ACTH峰值,这些试验在治疗后0、2和6个月重复进行。泼尼松龙治疗停止后的早晨皮质醇和ACTH值受到抑制。第一次CRH刺激试验中的皮质醇峰值范围为5.1至25.4μg/dL,21例患者中有17例低于20μg/dL,但在泼尼松龙治疗后6个月时所有患者的皮质醇值均恢复至超过14.6μg/dL。泼尼松龙治疗后09:00时的皮质醇值与随后的CRH刺激试验中的皮质醇峰值之间存在显著正相关(r = 0.727,p < 0.001)。我们得出结论,尽管使用糖皮质激素的时间较短且剂量相对较小,但接受IVIG联合泼尼松龙治疗的KD患儿中,肾上腺抑制的发生率仍可能较高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验